Navigation Links
Microarray technology for tailoring breast cancer therapy

Microarray technology could be used to tailor therapy according to the individual, and prevent breast cancer patients from having to undergo painful unsuccessful therapies. In a study published in the journal Breast Cancer Research, researchers analysed tumour tissue samples and identified a group of64 genes that can be used to predict a patient's response in the five years after adjuvant therapy for breast cancer. Identifying patients whose breast tumours express these genes could potentially be used to predict which patients would not benefit from adjuvant therapy, and avoid patients being given therapies with the potential of causing more harm than good.

A team of researchers led by Jonas Bergh from the Karolinska Institutet in Stockholm, Sweden, analysed the gene expression profiles of 159 breast cancer patients using DNA microarray analysis. From these samples they identified the genetic signatures shown by 38 patients who had a poor prognosis - defined as relapse or death from any cause within 5 years. The remaining 121 patients were defined as the 'good prognosis' group. The researchers also used gene expression profiling to separate patients who did well with and without adjuvant therapy, and those whose tumours failed to respond to treatment.

An analysis of the genes expressed in the tumours of all 159 patients showed that 64 genes were used to separate the patients with good and poor prognoses.The researchers then tested the predictive value of the group of 64 genes compared with three currently used clinical markers. Using the expression patterns of the 64 genes identified by the researchers gave significantly better(P=0.007) prediction rates than histological grading, tumour stage and age - which are all accepted prognostic markers for breast cancer.

The present lack of criteria to help tailor breast cancer treatment to individual patients indicates a need to develop new techniques for better prediction of how patients will respond to adjuvant treatments. The researchers suggest that the technique of DNA microarray analysis could be developed to help breast cancer patients who do not benefit from adjuvant therapy, and avoid painful unnecessary treatments and wastage of healthcare resources.


'"/>

Source:Karolinska Institutet


Related biology news :

1. Affymetrix Unveils Plans to Double Plant and Animal Genome Microarray Offering
2. Study Demonstrates Gene Expression Microarrays are Comparable and Reproducible
3. Breakthrough Microarray-based Technology for the Study of Cancer
4. Nanogen Issued Patent for Electronic Microarray With Memory
5. Characterizing Skin Cancer by Microarrays
6. Microarrays as phenotype
7. $6.5 Million Grant for Microarray Center at Yale School of Medicine
8. Agilent Technologies Introduces First Commercial Mouse Microarray for Comparative Genomic Hybridization Research
9. Genomatix Microarray Analysis Pipeline achieves Affymetrix GeneChip compatible?status
10. Novel technology detects human DNA mutations
11. Novel antiviral technology inhibits RSV infection in mice
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/7/2017)... LAKE CITY , March 7, 2017   ... that help top global companies identify the best talent, ... as Chief Sales Officer (CSO) and Diana ... Kucer,s appointments round out a seasoned executive team poised to ... and beyond, building on a year of record bookings ...
(Date:3/2/2017)... Summary This report provides all ... and its partnering interests and activities since 2010. ... The Partnering Deals and Alliance since 2010 report provides ... of the world,s leading life sciences companies. ... ensure inclusion of the most up to date deal ...
(Date:3/1/2017)... , March 1, 2017  Aware, Inc. (NASDAQ: AWRE), ... that Richard P. Moberg has resigned, effective ... and Chief Financial Officer and Treasurer of Aware citing ... serve as a member of the Board of Directors ... Aware,s co-Chief Executive Officer and co-President, General Counsel has ...
Breaking Biology News(10 mins):
(Date:3/27/2017)... ... 2017 , ... A research team led by Mai Lam, ... Video Journal, the world’s first peer-reviewed scientific video journal. The article demonstrates a ... disease (CAD). Lam is an assistant professor at the Department of Biomedical Engineering ...
(Date:3/27/2017)... Neurotrope, Inc. (OTCQB: NTRP),  a clinical-stage ... including Alzheimer,s disease, today announced that it has ... Company,s common stock on the NASDAQ Capital Market ... a unit of the NASDAQ OMX Group.  In ... Bell at the NASDAQ MarketSite in Times Square, New ...
(Date:3/24/2017)... , Mar. 24, 2017 Research and ... Cell (hESC) Research - Global Strategic Business Report" report to ... ... (hESC) Research in US$ Million. Annual estimates and forecasts are provided ... derived from primary and secondary research. The report ...
(Date:3/24/2017)... 24, 2017   Sienna Biopharmaceuticals, Inc. , a ... announced that Richard Peterson will join the ... Peterson, who brings more than two decades of ... who is retiring at the end of April but ... Peterson joins Sienna from Novan, Inc., where he served ...
Breaking Biology Technology: